A Novel Standard for Hepatocellular Carcinoma Screening Intensity After Hepatitis C Elimination

Akio Miyasaka,1,2 Yuichi Yoshida,1,2 Akiko Suzuki,1 Kei Sawara,1,3 Yasuhiro Takikawa1 1Division of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Shiwa-gun, Iwate, Japan; 2Department of Gastroenterology, Iwate Prefectural Ninohe Hospital, Ninohe, Iwate, Jap...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Miyasaka A, Yoshida Y, Suzuki A, Sawara K, Takikawa Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	hepatocellular carcinoma antiviral agents sustained virological response Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/faef1734927145a3979fb6afe189eef9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:faef1734927145a3979fb6afe189eef9
record_format	dspace
spelling	oai:doaj.org-article:faef1734927145a3979fb6afe189eef92021-11-28T19:13:10ZA Novel Standard for Hepatocellular Carcinoma Screening Intensity After Hepatitis C Elimination1178-7074https://doaj.org/article/faef1734927145a3979fb6afe189eef92021-11-01T00:00:00Zhttps://www.dovepress.com/a-novel-standard-for-hepatocellular-carcinoma-screening-intensity-afte-peer-reviewed-fulltext-article-IJGMhttps://doaj.org/toc/1178-7074Akio Miyasaka,1,2 Yuichi Yoshida,1,2 Akiko Suzuki,1 Kei Sawara,1,3 Yasuhiro Takikawa1 1Division of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Shiwa-gun, Iwate, Japan; 2Department of Gastroenterology, Iwate Prefectural Ninohe Hospital, Ninohe, Iwate, Japan; 3Department of Gastroenterology, Iwate Prefectural Kamaishi Hospital, Kamaishi, Iwate, JapanCorrespondence: Akio MiyasakaDivision of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 2-1-1 Idaidori, Yahaba-cho, Shiwa-gun, Iwate, 028-3695, JapanTel +81-19-613-7111Fax +81-19-907-7166Email akimiya@iwate-med.ac.jpPurpose: To investigate long-term incidence of hepatocellular carcinoma (HCC) and the factors associated with HCC occurrence after achieving sustained virological response (SVR) by direct-acting antiviral agent (DAA) treatment for hepatitis C virus (HCV).Methods: A total of 476 patients (male 227, female 249; median age 68) with chronic HCV infection who were treated with DAAs and achieved SVR were analyzed. The incidence of HCC and factors related to the development of HCC after HCV elimination were evaluated.Results: The median observation period was 46.4 months. During this period, 40 patients developed HCC. The incidence rates of HCC were 3.7%, 6.0%, 7.1%, 9.3%, and 10.6% at 1, 2, 3, 4, and 5 years post-SVR12, respectively. Multivariate analysis with pre-treatment factors revealed that platelet count, α-fetoprotein, fibrosis-4 (Fib-4) index, and previous HCC history were independent factors that contributed to development of HCC post-SVR following DAA treatment. Of these factors, previous HCC history was the most significant, followed by Fib-4 index. Using these two factors, a novel scoring system was established. The presence of previous HCC history was scored as 2, and then, the absence of previous HCC history was stratified by Fib-4 index (≥ 3.07, 1; < 3.07, 0). The HCC occurrence rate at 5 years was 0.4% in the 0-point group, 6.8% in the 1-point group, and 55.6% in the 2-point group, respectively.Conclusion: Fib-4 index and previous HCC history were independent predictors for development of HCC after DAA treatment. Patients with these risk factors require careful observation.Keywords: hepatocellular carcinoma, antiviral agents, sustained virological responseMiyasaka AYoshida YSuzuki ASawara KTakikawa YDove Medical Pressarticlehepatocellular carcinomaantiviral agentssustained virological responseMedicine (General)R5-920ENInternational Journal of General Medicine, Vol Volume 14, Pp 8935-8943 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	hepatocellular carcinoma antiviral agents sustained virological response Medicine (General) R5-920
spellingShingle	hepatocellular carcinoma antiviral agents sustained virological response Medicine (General) R5-920 Miyasaka A Yoshida Y Suzuki A Sawara K Takikawa Y A Novel Standard for Hepatocellular Carcinoma Screening Intensity After Hepatitis C Elimination
description	Akio Miyasaka,1,2 Yuichi Yoshida,1,2 Akiko Suzuki,1 Kei Sawara,1,3 Yasuhiro Takikawa1 1Division of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Shiwa-gun, Iwate, Japan; 2Department of Gastroenterology, Iwate Prefectural Ninohe Hospital, Ninohe, Iwate, Japan; 3Department of Gastroenterology, Iwate Prefectural Kamaishi Hospital, Kamaishi, Iwate, JapanCorrespondence: Akio MiyasakaDivision of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 2-1-1 Idaidori, Yahaba-cho, Shiwa-gun, Iwate, 028-3695, JapanTel +81-19-613-7111Fax +81-19-907-7166Email akimiya@iwate-med.ac.jpPurpose: To investigate long-term incidence of hepatocellular carcinoma (HCC) and the factors associated with HCC occurrence after achieving sustained virological response (SVR) by direct-acting antiviral agent (DAA) treatment for hepatitis C virus (HCV).Methods: A total of 476 patients (male 227, female 249; median age 68) with chronic HCV infection who were treated with DAAs and achieved SVR were analyzed. The incidence of HCC and factors related to the development of HCC after HCV elimination were evaluated.Results: The median observation period was 46.4 months. During this period, 40 patients developed HCC. The incidence rates of HCC were 3.7%, 6.0%, 7.1%, 9.3%, and 10.6% at 1, 2, 3, 4, and 5 years post-SVR12, respectively. Multivariate analysis with pre-treatment factors revealed that platelet count, α-fetoprotein, fibrosis-4 (Fib-4) index, and previous HCC history were independent factors that contributed to development of HCC post-SVR following DAA treatment. Of these factors, previous HCC history was the most significant, followed by Fib-4 index. Using these two factors, a novel scoring system was established. The presence of previous HCC history was scored as 2, and then, the absence of previous HCC history was stratified by Fib-4 index (≥ 3.07, 1; < 3.07, 0). The HCC occurrence rate at 5 years was 0.4% in the 0-point group, 6.8% in the 1-point group, and 55.6% in the 2-point group, respectively.Conclusion: Fib-4 index and previous HCC history were independent predictors for development of HCC after DAA treatment. Patients with these risk factors require careful observation.Keywords: hepatocellular carcinoma, antiviral agents, sustained virological response
format	article
author	Miyasaka A Yoshida Y Suzuki A Sawara K Takikawa Y
author_facet	Miyasaka A Yoshida Y Suzuki A Sawara K Takikawa Y
author_sort	Miyasaka A
title	A Novel Standard for Hepatocellular Carcinoma Screening Intensity After Hepatitis C Elimination
title_short	A Novel Standard for Hepatocellular Carcinoma Screening Intensity After Hepatitis C Elimination
title_full	A Novel Standard for Hepatocellular Carcinoma Screening Intensity After Hepatitis C Elimination
title_fullStr	A Novel Standard for Hepatocellular Carcinoma Screening Intensity After Hepatitis C Elimination
title_full_unstemmed	A Novel Standard for Hepatocellular Carcinoma Screening Intensity After Hepatitis C Elimination
title_sort	novel standard for hepatocellular carcinoma screening intensity after hepatitis c elimination
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/faef1734927145a3979fb6afe189eef9
work_keys_str_mv	AT miyasakaa anovelstandardforhepatocellularcarcinomascreeningintensityafterhepatitiscelimination AT yoshiday anovelstandardforhepatocellularcarcinomascreeningintensityafterhepatitiscelimination AT suzukia anovelstandardforhepatocellularcarcinomascreeningintensityafterhepatitiscelimination AT sawarak anovelstandardforhepatocellularcarcinomascreeningintensityafterhepatitiscelimination AT takikaway anovelstandardforhepatocellularcarcinomascreeningintensityafterhepatitiscelimination AT miyasakaa novelstandardforhepatocellularcarcinomascreeningintensityafterhepatitiscelimination AT yoshiday novelstandardforhepatocellularcarcinomascreeningintensityafterhepatitiscelimination AT suzukia novelstandardforhepatocellularcarcinomascreeningintensityafterhepatitiscelimination AT sawarak novelstandardforhepatocellularcarcinomascreeningintensityafterhepatitiscelimination AT takikaway novelstandardforhepatocellularcarcinomascreeningintensityafterhepatitiscelimination
_version_	1718407810755067904

A Novel Standard for Hepatocellular Carcinoma Screening Intensity After Hepatitis C Elimination

Ejemplares similares